ConductScience.org, home

Paper35330833

Comparative Efficacy of Different Drugs for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Bayesian Network Meta-Analysis.

Fan Z and 4 others. Front Pharmacol, 2022. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. Comparative Efficacy of Different Drugs for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Bayesian Network Meta-Analysis. Papers, record 35330833. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35330833

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparative Efficacy of Different Drugs for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Bayesian Network Meta-Analysis.
PubMed
Journal
Front Pharmacol
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
1.14
iCite
Revised in PubMed
2022-10-12
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fan ZZhinan
2Shi HHongjin
3Zhang JJinsong
4Wang HHaifeng
5Wang JJiansong

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in35950379Benign Prostatic Hyperplasia.https://conductscience.org/library/papers/35950379

Source PubMed

Download CSV of comments and corrections

References77

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130574201Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience.Ther Adv Urol2018https://conductscience.org/library/papers/30574201PubMed
217211442Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.Prostate Cancer Prostatic Dis2007https://conductscience.org/library/papers/17211442PubMed
321871706
Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
Eur Urol2011https://conductscience.org/library/papers/21871706PubMed
428508455
A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms.
Int J Clin Pract2017https://conductscience.org/library/papers/28508455PubMed
512887479
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
BJU Int2003https://conductscience.org/library/papers/12887479PubMed
626030634The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.Ann Intern Med2015https://conductscience.org/library/papers/26030634PubMed
722405510A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.Eur Urol2012https://conductscience.org/library/papers/22405510PubMed
817010005Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.Int J Urol2006https://conductscience.org/library/papers/17010005PubMed
926211817Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis.Curr Med Res Opin2015https://conductscience.org/library/papers/26211817PubMed
1010720857
Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
Eur Urol2000https://conductscience.org/library/papers/10720857PubMed
1118281145A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Eur Urol2008https://conductscience.org/library/papers/18281145PubMed
1218638006Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study.J Sex Med2008https://conductscience.org/library/papers/18638006PubMed
1332110593Study of correlation of urodynamic profile with symptom scoring and ultrasonographic parameters in patients with benign prostatic hyperplasia.J Family Med Prim Care2020https://conductscience.org/library/papers/32110593PubMed
1422704110Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men.J Urol2012https://conductscience.org/library/papers/22704110PubMed
1515839922Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.BJU Int2005https://conductscience.org/library/papers/15839922PubMed
1630251330
Effect of tadalafil add-on therapy in patients with persistant storage symptoms refractory to α1 -adrenoceptor antagonist monotherapy for benign prostatic hyperplasia: A randomized pilot trial comparing tadalafil and solifenacin.
Low Urin Tract Symptoms2019https://conductscience.org/library/papers/30251330PubMed
1721109344
Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
Eur Urol2011https://conductscience.org/library/papers/21109344PubMed
1834879880Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019.Mil Med Res2021https://conductscience.org/library/papers/34879880PubMed
1923953605Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study.Urology2013https://conductscience.org/library/papers/23953605PubMed
2019070418Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.Eur Urol2009https://conductscience.org/library/papers/19070418PubMed

See all 77 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
41879994[Pharmacotherapy of benign prostatic syndrome : Medications, innovations and future prospects].Urologie2026https://conductscience.org/library/papers/41879994PubMed
41305716Identification of biomarkers of Shenhailong formula in benign prostatic hyperplasia treatment: An observation study using network pharmacology and Mendelian randomization analysis.Medicine (Baltimore)2025https://conductscience.org/library/papers/41305716PubMed
40873873
Comparative efficacy and safety of silodosin and tadalafil combination or monotherapy for treating lower urinary tract symptoms due to benign prostatic obstruction: A systematic review and meta-analysis.
Cent European J Urol2025https://conductscience.org/library/papers/40873873PubMed
40301381Associations between the risk of LUTS/BPH and the number and class of chronic diseases among middle-aged and elder men.Sci Rep2025https://conductscience.org/library/papers/40301381PubMed
39789390Technological innovation of HoLEP: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.World J Urol2025https://conductscience.org/library/papers/39789390PubMed
38158423
A correlation study between prostate necrosis rate calculated by 3D Slicer software and clinical efficacy of prostatic artery embolization, along with an analysis of predictors of clinical success after prostatic artery embolization.
Abdom Radiol (NY)2024https://conductscience.org/library/papers/38158423PubMed
37943844Diacerein provokes apoptosis, improves redox balance, and downregulates PCNA and TNF-α in a rat model of testosterone-induced benign prostatic hyperplasia: A new non-invasive approach.PLoS One2023https://conductscience.org/library/papers/37943844PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ADRB3155PubTator's text mininghttps://conductscience.org/library/genes/155NCBI Gene
PDE5A8654PubTator's text mininghttps://conductscience.org/library/genes/8654NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35330833

GET https://conductscience.org/api/papers/v1/35330833/references?page=2